COMMUNIQUÉS West-GlobeNewswire

Fortress Biotech Announces Aevitas Therapeutics Enters Sponsored Research Agreement with the University of Pennsylvania to Advance AAV Gene Therapy Technology
06/08/2018
Agreement drives further testing of Aevitas’ AAV gene therapy technology in animal models of complement-mediated diseases NEW YORK, Aug. 06, 2018 (GLOBE NEWSWIRE) -- Fortress Biotech (NASDAQ:FBIO) (“Fortress”), a [...]
BioSig Technologies Added to LD Micro Index
06/08/2018
Santa Monica, CA, Aug. 06, 2018 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. ( BSGM ), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology [...]
TG Therapeutics, Inc. to Host Conference Call on Second Quarter 2018 Financial Results and Business Update
06/08/2018
Investor Conference Call to be tomorrow, Tuesday, August 7, 2018 at 4:30pm ET NEW YORK, Aug. 06, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held [...]
Indication for Use of SAVI SCOUT® Wire-Free Radar Breast Localization System Expands to Include Localization of Soft Tissue
06/08/2018
The SCOUT reflector can now be used to mark soft tissue sites including lymph nodes ALISO VIEJO, Calif., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Cianna Medical, Inc., the world leader in wire-free breast localization, [...]
VIVUS Appoints Kenneth Suh as President
06/08/2018
CAMPBELL, Calif., Aug. 06, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced the appointment of Ken Suh to the position of President. Previously, Mr. Suh [...]
Otonomy Announces OTIPRIO® Co-Promotion Agreement with Mission Pharmacal for Acute Otitis Externa Indication
06/08/2018
SAN DIEGO, Aug. 06, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced the signing of a co-promotion [...]
AMAG Pharmaceuticals Appoints Brian Robinson, M.D. as Senior Vice President of Medical Affairs
06/08/2018
WALTHAM, Mass., Aug. 06, 2018 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced the appointment of Brian Robinson, M.D. as senior vice president, medical affairs, reporting into Julie Krop, M. [...]
Kiniksa Reports Second Quarter 2018 Financial Results and Pipeline Progress
06/08/2018
– Rilonacept advancing toward pivotal Phase 3 clinical trial in 2H 2018 following recent End-of-Phase 2 communication with FDA – – KPL-716 single-dose Phase 1a/1b Last Subject Last Visit achieved; clinical trial data [...]
Ovid Therapeutics Announces Positive Topline Data from Phase 2 STARS Trial of OV101 for the Treatment of Angelman Syndrome
06/08/2018
-- OV101 achieved primary endpoint of safety and tolerability -- -- Robust and statistically significant improvement (p=0.0006) in the first prespecified efficacy endpoint (CGI-I) observed at 12 weeks of treatment in [...]
miRagen Therapeutics and The Leukemia & Lymphoma Society® Enter Into an Agreement to Facilitate the Development of Cobomarsen in Cutaneous T-Cell Lymphoma
06/08/2018
BOULDER, Colo. and RYE BROOK, N.Y., Aug. 06, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted [...]
Cara Therapeutics Appoints Christopher A. Posner to Board of Directors
06/08/2018
STAMFORD, Conn., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and [...]
Elite Pharmaceuticals Receives FDA Approval for Generic Methadone Hydrochloride Tablets
06/08/2018
NORTHVALE, N.J., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, [...]
Antares Pharma Enters Into Development Agreement With Pfizer Inc.
06/08/2018
EWING, N.J., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“Antares”) today announced that it has entered into an agreement with Pfizer Inc. (“Pfizer”) to develop a combination drug device [...]
Neuralstem Appoints Jim Scully as Interim Chief Executive Officer
06/08/2018
William Oldaker Expands Role and is Named Chairman of the Board GERMANTOWN, Md., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system [...]
iTeos Therapeutics to Participate in Upcoming U.S. Conferences in August
06/08/2018
iTeos Therapeutics to Participate in Upcoming U.S. Conferences in August Gosselies, Belgium – August 6, 2018 – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announced that [...]
Complete Response Letter Issued for REMOXY™
06/08/2018
- Corporate Reorganization Expected Shortly - AUSTIN, Texas, Aug. 06, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE) today announced it had received a Complete Response Letter (CRL) from the U.S. Food [...]
Oxford BioMedica, UK Cystic Fibrosis Gene Therapy Consortium, Boehringer Ingelheim and Imperial Innovations Form Partnership to Develop a Novel Gene Therapy Treatment for Cystic Fibrosis
06/08/2018
Oxford BioMedica, UK Cystic Fibrosis Gene Therapy Consortium, Boehringer Ingelheim and Imperial Innovations Form Partnership to Develop a Novel Gene Therapy Treatment for Cystic Fibrosis Oxford, UK – 6 August 2018: [...]
Angiochem Announces Special Protocol Assessment (SPA) with US Food and Drug Administration (FDA)
06/08/2018
MONTREAL, Aug. 06, 2018 (GLOBE NEWSWIRE) -- Angiochem Inc. (“Angiochem”) announced today that it has reached an agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on [...]
Unum Therapeutics to Host Second Quarter 2018 Financial Results Conference Call and Webcast on August 13, 2018 at 5:00 P.M. ET
06/08/2018
CAMBRIDGE, Mass., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (Nasdaq:UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies based on its novel, universal [...]

Pages